Skip to main content

REVIEW article

Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1454747

Cutting-edge Approaches to B-cell Depletion in Autoimmune Diseases

Provisionally accepted
William H. Robinson William H. Robinson 1*David Fiorentino David Fiorentino 2Lorinda Chung Lorinda Chung 1,3Larry W. Moreland Larry W. Moreland 4Malavika Deodhar Malavika Deodhar 5Mary Beth Harler Mary Beth Harler 5Carrie Saulsbery Carrie Saulsbery 5Rebecca Kunder Rebecca Kunder 5
  • 1 Division of Immunology and Rheumatology, Department of Medicine, School of Medicine, Stanford University, Palo Alto, United States
  • 2 Department of Dermatology, School of Medicine, Stanford University, Stanford, United States
  • 3 Other, Palo Alto, CA, United States
  • 4 Division of Rheumatology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, United States
  • 5 Other, Mountain View, CA, United States

The final, formatted version of the article will be published soon.

    This article provides an in-depth examination of current and emerging modalities of B-cell depletion therapy (BCDT), with a focus on effector-function-enhanced monoclonal antibodies, chimeric antigen receptor T-cell treatment, and T-cell engagers. Leveraging the demonstrated efficacy and safety of BCDT modalities in oncology, these approaches are now being applied for the treatment of autoimmune conditions, such as rheumatoid arthritis and systemic lupus erythematosus. We briefly discuss the timeline of BCDT innovations, review the molecule design and mechanism of action of each BCDT modality, and discuss their potential advantages and limitations with respect to efficacy and safety. We also provide an overview of the current knowledge of BCDTs for treating autoimmune disease, including a comprehensive listing of registered clinical trials testing BCDT modalities in autoimmune disease.

    Keywords: autoimmune disease, B-cell depletion therapy, effectorfunction-enhanced monoclonal antibodies, imvotamab, t-cell engager

    Received: 25 Jun 2024; Accepted: 13 Sep 2024.

    Copyright: © 2024 Robinson, Fiorentino, Chung, Moreland, Deodhar, Harler, Saulsbery and Kunder. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: William H. Robinson, Division of Immunology and Rheumatology, Department of Medicine, School of Medicine, Stanford University, Palo Alto, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.